PCSK9 inhibitors and cardiovascular disease: Heralding a new therapeutic era

Current Opinion in Lipidology

Volumn 26, Issue 6, 2015, Pages 511-520

  Chapman, M John ^a   Stock, Jane K ^b   Ginsberg, Henry N ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b PCSK9 Forum Secretariat   (United Kingdom)

^c Department of Medicine ^*  (United States)

Author keywords

alirocumab; cardiovascular risk; evolocumab; low density lipoprotein cholesterol; proprotein convertase subtilisin kexin type 9 inhibitors

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; PROTEINASE INHIBITOR; SERINE PROTEINASE;

ATHEROSCLEROSIS; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CLINICAL PRACTICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GAIN OF FUNCTION MUTATION; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; OUTCOME ASSESSMENT; PLASMA CLEARANCE; PRIORITY JOURNAL; REVIEW; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SAFETY;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; MOLECULAR TARGETED THERAPY; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; PROTEASE INHIBITORS; SAFETY; SERINE ENDOPEPTIDASES;

EID: 84957697378     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000239     Document Type: Review

References (67)

1. World Health Organization. Top 10 causes of death. http://www.who.int/mediacentre/factsheets/fs310/en/index2.html. [Accessed 18 August 2015]
2. World Economic Forum and Harvard School of Public Health. The global economic burden of Noncommunicable Diseases. 2011. http://www3.wefor um.org/docs/WEF-Harvard-HE-GlobalEconomicBurdenNonCommunicable-Diseases-2011.pdf. [Accessed 3 September 2015]
3. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 2015; 161:161-172.
4. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015; 65:1552-1561.
5. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
6. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490a.
7. Béliard S, Carreau V, Carrié A, et al. Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. Atherosclerosis 2014; 234:136-141.
8. Mundal L, Sarancic M, Ose L, et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. J Am Heart Assoc 2014; 3:e001236.
9. Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun 2014; 5:5068.
10. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy. European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J 2015; 36:1012-1022.
11. Abifadel M, Elbitar S, El Khoury P, et al. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep 2014; 16:439.
12. Saavedra YG, Dufour R, Davignon J, Baass A. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a crosssectional cohort study. Arterioscler Thromb Vasc Biol 2014; 34:2700-2705.
13. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res 2014; 114:1022-1036.
14. Scotti E, Calamai M, Goulbourne CN, et al. IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor. Mol Cell Biol 2013; 33:1503-1514.
15. McKenney JM. Understanding PCSK9 and anti-PCSK9 therapies. J Clin Lipidol 2015; 9:170-186.
16. Lambert G, Petrides F, Chatelais M, et al. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of lowdensity lipoprotein receptor defects. J Am Coll Cardiol 2014; 63:2365-2373.
17. Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 2015; 115:1212-1221.
18. Stein E, Koren M, Honarpour N, et al. Clinical equivalence of evolocumab 140mg every 2 weeks and 420 mg monthly dosing regimens: a pooled analysis of 3146 patients. J Am Coll Cardiol 2015; 65 (10-S). doi:10.1016/S0735-1097(15)61368-7.
19. Fitzgerald K, Kallend D, White S, et al. A phase 1, randomized, placebocontrolled, single ascending and multiple dose study of subcutaneously administered ALN-PCSSC in subjects with elevated low density lipoprotein cholesterol. Eur Heart J 2015; 36 (Abstract Supplement):309.
20. van Poelgeest EP, Hodges MR, Moerland M, et al. Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a firstin-human randomized, placebo-controlled trial. Br J Clin Pharmacol 2015. [Epub ahead of print]
21. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:331-340.
22. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015. [Epub ahead of print]
23. Ginsberg HN, Rader DJ, Raal FJ, et al. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia [abstract]. Circulation 2014; 130:2119.
24. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146-2157.
25. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013; 128:2113-2120.
26. Lambert G, Chatelais M, Petrides F, et al. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab. J Am Coll Cardiol 2014; 64:2299-2300.
27. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:341-350.
28. Santos RD, Watts GF. Familial hypercholesterolaemia: PCSK9 inhibitors are coming. Lancet 2015; 385:307-310.
29. Raal FJ, Hovingh GK, Blom D, et al. A. Long-term treatment with evolocumab in patients with homozygous familial hypercholesterolaemia (HoFH): Interim results from the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG) Study. ClinicalTrials.gov Identifier: NCT01624142. Abstract 1042. International Symposium on Atherosclerosis, 23-25 May 2015, Amsterdam, The Netherlands.
30. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36:2425-2437.
31. Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders (HAUSER-RCT). Clinical Trials Identifier NCT02392559. https://clinicaltrials.gov/ct2/show/NCT02392559.
32. Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014; 311:1870-1882.
33. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370:1809-1819.
34. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500-1509.
35. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014; 129:234-243.
36. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J 2015; 169:906-915.
37. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015; 36:1186-1194.
38. Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab 2015; 100:3140-3148.
39. Bays H, Farnier M, Gaudet D, et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II [abstract]. Circulation 2014; 130:2118-2119.
40. Roth E, Rader D, Moriarty Patrick M, et al. Phase 3 randomized trial evaluating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE I. Abstract 254, International Symposium on Atherosclerosis, 23-25 May 2015, Amsterdam, The Netherlands. http://www.isa-2015.com/wp-content/uploads/2015/05/ISA2015-abstracts-251-500.pdf.
41. Stroes E, Baccara-Dinet MT, Civeira F, et al. Alirocumab in patients with hypercholesterolemia not on statin therapy - the ODYSSEY CHOICE II study. Abstract 269, International Symposium on Atherosclerosis, 23-25 May 2015, Amsterdam, The Netherlands. http://www.isa-2015.com/wp-con tent/uploads/2015/05/ISA2015-abstracts-251-500.pdf.
42. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1489-1499.
43. Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014; 35:2249-2259.
44. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 2015; 13:123.
45. Rosenson RS, Jacobson T, Preiss D, et al. Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed dyslipidaemia. Abstract 252, International Symposium on Atherosclerosis, 23-25 May 2015, Amsterdam, The Netherlands. http://www.isa-2015.com/wp-content/uploads/2015/05/ISA2015-abstracts-251-500.pdf.
46. Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008; 7:22.
47. Krempf M, Bergeron J, Elassal J, et al. Efficacy of alirocumab according to background statin intensity and other lipid-lowering therapy in heterozygous familial hypercholesterolemia or high CV risk populations: phase 3 subgroup analyses [abstract]. Atherosclerosis 2015; 241:e21.
48. Stein EA, Wasserman SM, Dias C, et al. AMG-145. Drugs Fut 2013; 38:451.
49. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63:2541-2548.
50. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015. [Epub ahead of print]
51. Reyes-Soffer G, Ramakrishnan S, Ginsberg HN, et al. Effects of a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor (PCSK9), alirocumab, on lipid and lipoprotein metabolism in healthy human subjects. Abstract 644, International Symposium on Atherosclerosis, 23-25 May 2015, Amsterdam, The Netherlands.http://www.isa-2015.com/wp-content/uploads/2015/05/ISA-2015-abstracts-501-750.pdf.
52. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013; 273:6-30.
53. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014; 63:470-477.
54. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63:1278-1288.
55. Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014; 114:711-715.
56. Romagnuolo R, Scipione C, Boffa MB, et al. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015; 290:11649-11662.
57. Food and Drug Administration Center for Drug Evaluation and Research. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting. June 9, 2015. Briefing document BLA 125559. Praluent (alirocumab) injection. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM449865.pdf.
58. Food and Drug Administration Center for Drug Evaluation and Research. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting. June 10, 2015. Briefing document. Repatha (evolocumab) injection. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM450072.pdf.
59. Swiger KJ, Martin SS. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug Saf 2015; 38:519-526.
60. EBBINGHAUS: Evaluating PCSK9 Binding anti Body Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects. ClinicalTrials.gov Identifier: NCT02207634. https://clinicaltrials.gov/ct2/show/NCT02207634.
61. Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 2015; 30:348-358.
62. Bonnefond A, Yengo L, Le May C, et al. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis. Diabetologia 2015; 58:2051-2055.
63. Holman RR, Koren MJ, Roth E, et al. Evaluation of the glycemic effects and efficacy and safety of evolocumab (AMG 145) in subjects with or without dysglycemia or metabolic syndrome. Abstract 258-OR. 75th Scientific Sessions, American Diabetes Association, June 5-9, 2015, Boston, Massachusetts. http://app.core-apps.com/tristar-ada15/abstract/160858d53930b 598d64b10f3934b4ef6.
64. Auer J, Berent R, Primus C. PCSK9 inhibitors and cardiovascular events. N Engl J Med 2015; 373:773-774.
65. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: asystematic review and meta-analysis. Ann Intern Med 2015; 163:40-51.
66. Walley KR, Francis GA, Opal SM, et al. The central role of PCSK9 in septic pathogen lipid transport and clearance. Am J Respir Crit Care Med 2015. [Epub ahead of print]
67. Walley KR, Thain KR, Russell JA, et al. Pcsk9 is a critical regulator of the innate immune response and septic shock outcome. Science Transl Med 2014; 6:258ra143.